Slide 1: First Quarter Fiscal 2026 Earnings Call
Cencora, Inc. First Quarter Fiscal 2026 Earnings Call February 4, 2026
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securit
Slide 3: Creating differentiated value for our stakeholders
cencora Creating differentiated value for our stakeholders Our purpose: We are united in our responsibility to create healthier futures We use our global reach and local community expertise to connect patients to pharmaceuticals through strategic partnerships with manufacturers and healthcare provid
Slide 4: First quarter highlights & strategic overview
First quarter highlights & strategic overview Company highlights Financial highlights & fiscal 2026 guidance • Cencora completed its acquisition of the majority of the • Adjusted diluted EPS(1) increased 9.4% year-over-year to outstanding equity interests that it did not own in $4.08. OneOncology, a
Slide 5: Financial results
cencora Financial results
Slide 6: Q1 fiscal 2026 financial summary
Q1 fiscal 2026 Consolidated results GAAP Adjusted (non-GAAP)(1) financial summary Revenue y/y% $85.9B 5.5% $85.9B 5.5% 5.5% Gross profit $3.1B $3.0B y/y% 20.1% 18.1% Revenue growth y/y 11.9% Operating expenses $2.3B $1.9B Consolidated y/y% 24.8% 21.7% adjusted operating income(1) growth y/y Operatin
Slide 7: U.S. Healthcare Solutions segment
U.S. Healthcare Solutions segment Q1 fiscal 2026 financial results Q1 Q1 Financial results y/y% fiscal 2026 fiscal 2025 • Revenue increased 5.0% to $76.2 billion due to overall market growth largely driven Revenue $76.2B $72.6B 5.0% by unit volume growth, including increased sales of specialty produ
Slide 8: International Healthcare Solutions segment
International Healthcare Solutions segment Q1 fiscal 2026 financial results Constant Financial results Q1 Q1 y/y% currency(1) • Revenue increased 9.6% to $7.6 billion on (as reported) fiscal 2026 fiscal 2025 y/y% an as-reported basis, primarily due to growth in our European distribution Revenue $7.6
Slide 9: Other
Other Q1 fiscal 2026 financial results Q1 Q1 Financial results y/y% fiscal 2026 fiscal 2025 • Revenue increased 6.3% to $2.1 billion due to growth at MWI Animal Health and Revenue $2.1B $2.0B 6.3% Profarma, offset in part by a decrease in sales at our consulting services businesses. Operating income
Slide 10: Fiscal 2026 guidance
cencora Fiscal 2026 guidance =
Slide 11: Fiscal 2026 Guidance
Fiscal 2026 Guidance Consolidated Fiscal 2026 guidance Fiscal 2025 actuals Revenue 7% to 9% growth $321.3B Adjusted operating income(1) 11.5% to 13.5% growth $4.2B Adjusted diluted earnings per share(1) $17.45 to $17.75 $16.00 Net interest expense $480M to $500M $292M Adjusted effective tax rate(1)
Slide 12: Fiscal 2026 Guidance
Fiscal 2026 Guidance Segment As reported Constant currency(1) Recast Fiscal 2025(2) U.S. Healthcare Solutions(2) Revenue 7% to 9% growth $285.0B Operating income 14% to 16% growth $3.3B International Healthcare Solutions(2) Revenue 7% to 9% growth 6% to 8% growth $28.3B Operating income 5% to 8% gro
Slide 13: Advancing corporate responsibility initiatives to create healthier futures
Global Corporate Responsibility Building resilient and sustainable operations • Business Resilience: Performed physical risk assessments using climate models to inform operational planning. • Renewable Energy: World Courier facilities in Stockholm and Copenhagen began generating on-site solar energy
Slide 14: Appendix
cencora Appendix
Slide 15: GAAP to Non-GAAP Reconciliations
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended December 31, 2025 Income Net Income Diluted Operating Operating Before Income Tax Attributable Earnings Gross Profit Expenses Income Income Taxes Expense to Cencora Per Share GAAP $ 3,
Slide 16: GAAP to Non-GAAP Reconciliations
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended December 31, 2024 Net Income Operating Income Before Income Tax Attributable Diluted Earnings Gross Profit Expenses Operating Income Income Taxes Expense to Cencora Per Share GAAP $ 2,
Slide 17: Supplemental information regarding non-GAAP financial measures
Supplemental information regarding non-GAAP financial measures To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in
Slide 18: Supplemental information regarding non-GAAP financial measures (cont.)
Supplemental information regarding non-GAAP financial measures (cont.) • Adjusted net income attributable to Cencora: Adjusted net income attributable to the Company is a non-GAAP financial measure that excludes the same items that are described above. Management believes that this non-GAAP financia
Slide 19: Supplemental information regarding non-GAAP financial measures (cont.)
Supplemental information regarding non-GAAP financial measures (cont.) In addition, the Company has provided non-GAAP fiscal year 2026 guidance for diluted earnings per share, operating income, effective income tax rate, and free cash flow that excludes the same or similar items as those that are ex
Slide 20: Contact
Contact Bennett Murphy Senior Vice President, Investor Relations and Enterprise Productivity Bennett.Murphy@cencora.com 20